Raggam Reinhard B, Leitner Eva, Berg Jörg, Mühlbauer Gerhard, Marth Egon, Kessler Harald H
Molecular Diagnostics Laboratory, Institute of Hygiene, Medical University Graz, Universitaetsplatz 4, A-8010 Graz, Austria.
J Mol Diagn. 2005 Feb;7(1):133-8. doi: 10.1016/S1525-1578(10)60019-0.
A molecular assay for parallel detection of three bacteria, Chlamydia (C.) pneumoniae, Legionella (L.) spp., and Mycoplasma (M.) pneumoniae, in clinical specimens by a set of real-time polymerase chain reactions (PCRs) in a single run was evaluated. Bacterial DNAs were extracted by an automated DNA extraction protocol on the MagNA Pure LC System. Amplification and detection were done by real-time PCR on the LightCycler (LC) instrument. For amplification, specific oligonucleotides derived from the 16s rRNA genes of C. pneumoniae, L. spp., and M. pneumoniae were used. The three assays were complemented with an internal control (IC), a specially designed DNA fragment which contains the specific primer binding sites for the three PCRs. The IC was added to the samples, co-extracted, and co-amplified. Primers and hybridization probes were designed to suit one LC PCR program. LC PCRs were established, detection limits were determined, and clinical samples were tested. The detection limits were found between 5.0 and 0.5 IFU/CFU per PCR reaction for each of the bacteria. A total number of 100 clinical specimens were tested for validation of the molecular assay. Tested samples included 63 bronchoalveolar lavages (BALs) and 37 induced sputa specimens. The internal control was detected in all negative and low-positive samples; no inhibition was found throughout the whole study. Additionally, samples underwent testing by culture for L. spp., and M. pneumoniae; for C. pneumoniae, the serological microimmunofluorescence (MIF) test was used. In conclusion, the developed set of LC PCR assays permits parallel detection of C. pneumoniae, L. spp., and M. pneumoniae in a single LC run. This molecular assay may lead to accurate and early diagnosis of pneumonia produced by these three types of bacteria. The assay proved to be suitable for the high-throughput routine diagnostic laboratory.
评估了一种分子检测方法,该方法通过一组实时聚合酶链反应(PCR)在单次运行中对临床标本中的三种细菌——肺炎衣原体(C. pneumoniae)、嗜肺军团菌(L. spp.)和肺炎支原体(M. pneumoniae)进行平行检测。使用MagNA Pure LC系统上的自动化DNA提取方案提取细菌DNA。在LightCycler(LC)仪器上通过实时PCR进行扩增和检测。对于扩增,使用了源自肺炎衣原体、嗜肺军团菌和肺炎支原体16s rRNA基因的特异性寡核苷酸。这三种检测方法均配有内部对照(IC),即一个经过特殊设计的DNA片段,它包含这三种PCR的特异性引物结合位点。将IC添加到样本中,共同提取并共同扩增。设计引物和杂交探针以适应一个LC PCR程序。建立了LC PCR方法,确定了检测限,并对临床样本进行了检测。每种细菌在每个PCR反应中的检测限在5.0至0.5 IFU/CFU之间。总共测试了100份临床标本以验证该分子检测方法。测试样本包括63份支气管肺泡灌洗(BAL)样本和37份诱导痰标本。在所有阴性和低阳性样本中均检测到内部对照;在整个研究过程中未发现抑制现象。此外,样本还通过嗜肺军团菌和肺炎支原体培养进行检测;对于肺炎衣原体,使用血清学微量免疫荧光(MIF)试验。总之,所开发的这套LC PCR检测方法允许在单次LC运行中平行检测肺炎衣原体、嗜肺军团菌和肺炎支原体。这种分子检测方法可能有助于对这三种细菌引起的肺炎进行准确和早期诊断。该检测方法被证明适用于高通量常规诊断实验室。